In late April 2012. a new drug entered the market. The drug, known as Omontys, was manufactured by Affymax for the treatment of anemia in kidney dialysis patients. If you or a loved one was given Omontys as part of your treatment, then it is important to understand what has happened over the past year and what you should do if you have been hurt, or if you’ve lost a loved one.

The Omontys Timeline: April 2012 to April 2013

In order to understand the possible threat posed by Omontys and why some injuries may have been avoidable, it is important to know what happened over the past year:

  • April 2012: The U.S. Food and Drug Administration (FDA) approves Omontys for treatment of anemia in kidney dialysis patients.
  • August 2012: The FDA receives reports of serious allergic reactions and respiratory distress, possibly linked to Omontys.
  • February 22, 2013: In the approximately 10 months since the drug had entered the market, the FDA has received a total of 98 adverse event reports related to Omontys. Twelve deaths were reported, but it is unclear whether those patients died from Omontys or from other conditions. Some of the events included a severe allergic reaction known as anaphylaxis.
  • February 23, 2013: Affymax recalls all existing lots of Omontys on account of severe reactions and deaths associated with the drug.

The FDA has not yet officially recalled Omontys, and the drug’s future is currently unknown. More than 25,000 patients are believed to have received Omontys since April 2012.

Contact a Quad Cities Pharmaceutical Class Action Lawyer If You’ve Been Hurt

If you have been injured by Omontys, or if your loved one has died from this drug, then it is important to know your rights. Please contact an experienced Quad Cities class action attorney today to learn more about your rights and possible recovery. We can be reached via this website or by calling (800) 800-5678.

Jason F. Abraham
Connect with me
Helping car accident and personal injury victims throughout Wisconsin, Illinois and Iowa since 1993.